Diabetes mellitus can cause a decrease in tear secretion and film composition, resulting series of pathological changes such as the stability film, increased risk inflammation, peripheral neuropathy impairment meibomian glands, leading to dry eye. The imbalance inflammatory mediators diabetic patients injury ocular surface are main factors that aggravate Nod-like receptor protein 3 inflammasome...

Monoclonal antibodies are a promising new class of therapeutic agents that can be employed to target specific molecules of the immune system or any tissue. They are currently being tested in a number of clinical trials in autoimmune diseases such as multiple sclerosis (MS). One of these, the humanized monoclonal anti-CD25 antibody daclizumab (Zenapax), is directed against the interleukin-2 (IL-...

Introduction: Multiple sclerosis is a chronic inflammatory disease of central nervous system. The etiology of MS is slightly known, but genetic and environmental factors are reported. Vitamin D regulates gene expression and affects target cell functions. The aim of this study was to investigate the expression variation of IL-2 and IL-4 genes under vitamin D supplementation in patients with mult...

Cytokines and intrathecal IgG synthesis were determined in the cerebrospinal fluid (CSF) and sera to evaluate inflammatory activity in multiple sclerosis (MS) patients during clinical remission. Although the disease was stable, there had been a significant increase of proinflammatory cytokines such as TNFalpha and IFNgamma in the CSF and serum, with no significant changes of IL12 and IL10 produ...

CD8+ T cells induced by Plasmodium yoelii sporozoites develop into protective memory cells without undergoing changes in interleukin-7 receptor alpha (IL-7Ralpha) expression, differing from the development of memory CD8+ T cells against viruses, which is associated with enhanced IL-7Ralpha expression. This suggests a microbe-dependent diversity in the signals determining the development of memo...

background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reductio...